PATENT CLAIM ANALYSIS

Application Number: 16218353
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["514", "020800"]

Abstract:
The present disclosure provides pharmaceutical compositions and methods thereof for the treatment of age-related macular degeneration (AMD) in a subject by administering intravitreally a pharmaceutical composition adapted for gene therapy, comprising a vector having a nucleic acid sequence that encodes aflibercept.

Claim (Index 1):
A method of treating an eye condition or disease, the method comprising administering a unit dose of a pharmaceutical composition by intravitreal injection to an eye of a primate subject in need thereof, wherein the pharmaceutical composition comprises:\n (a) a rAAV2 variant comprising an amino acid sequence LGETTRP (SEQ ID NO: 4) inserted between positions 587 and 588 of capsid protein VP1, and a nucleic acid sequence encoding a polypeptide comprising a sequence having at least 95% homology to aflibercept, and (b) a pharmaceutically acceptable excipient.

Metadata:
- Claim Count in Document: 42.0
- Percentile: 98.0
- Lexical Diversity: 1.125
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15851650', '14281749', '13868453', '15058938', '15602096']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7081532173638346
- 35 USC 102 Novelty (BERT): 0.5107278610521927
- Combined Prediction Score: 0.6884106817326704
- Mean Citation Score: 245.46073
- Max Citation Score: 280.33154
- Similarity Product: 197.76720300760863

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test